Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month. Thursday, August 6, 2020 Event: William Blair Biotech Focus Conference 2020 Time: 12:00 pm ET *Fireside chat Thursday, August 13, 2020 Event: Canaccord Genuity 40 th Annual Growth Conference Time: 4:30 pm ET *Company overview and business
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) --Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month.
Thursday, August 6, 2020
Event: William Blair Biotech Focus Conference 2020
Time: 12:00 pm ET
*Fireside chat
Thursday, August 13, 2020
Event: Canaccord Genuity 40th Annual Growth Conference
Time: 4:30 pm ET
*Company overview and business update presentation
Live webcasts of these events will be available under the Investors and Media section of Aileron’s website at https://investors.aileronrx.com/. A replay of the webcasts will be archived on Aileron’s website for 30 days following the respective events.
About Aileron Therapeutics
At Aileron, we are focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.
In addition to potentially reducing or eliminating multiple side effects, ALRN-6924 may also improve patients’ quality of life and help them better tolerate chemotherapy, potentially allowing patients to complete their treatment without dose reductions or delays. Our long-term vision is to provide chemoprotection for patients with p53-mutated cancers, which represents approximately 50% of cancer patients, regardless of cancer type or chemotherapeutic drug. Visit us at aileronrx.com to learn more.
Investor Contacts:
Aileron Therapeutics
Richard Wanstall, SVP Chief Financial Officer
617-995-0900
rwanstall@aileronrx.com
Hans C. Vitzthum
LifeSci Advisors, LLC.
617-430-7578
hans@lifesciadvisors.com
Media Contact:
Liz Melone
617-256-6622
lmelone@aileronrx.com
